Navigation Links
Abuse-Deterrent Formulations of Purdue's OxyContin and Endo Pharmaceuticals' Opana ER Have Not Increased PCPs' Comfort When Prescribing These Products for Chronic Pain
Date:7/16/2013

BURLINGTON, Mass., July 16, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that despite the replacement of Purdue Pharma's OxyContin and Endo Pharmaceuticals' Opana ER with abuse-deterrent formulations, surveyed primary care physicians (PCPs) do not feel more comfortable prescribing these products for the treatment of chronic pain. In contrast, the majority of surveyed pain specialists report that they are more comfortable prescribing OxyContin and Opana ER now that the products feature abuse-deterrent properties.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The U.S. Physician & Payer Forum report entitled Chronic Pain: How Will U.S. Payers and Prescribers Shape Market Access for Recently Launched and Emerging Products? also finds that 57 percent and 53 percent of surveyed managed care organization (MCO) directors report that coverage of OxyContin and Opana ER has not changed as a result of the products' reformulation to be abuse-deterrent—suggesting that, in many patients, the cost to reimburse OxyContin and Opana ER may outweigh the advantages of the abuse-deterrent formulations. In cases where a non-abuse-deterrent generic opioid was available, MCO directors are likely to only reimburse an abuse-deterrent product in patients with a history of drug abuse—signaling that emerging abuse-deterrent formulations will still be subject to coverage restrictions.

The report also finds that cost will likewise be an important consideration for prescribing and reimbursement of new chronic pain therapies, most notably for Pfizer's novel anti-NGF therapy tanezumab. Seventy-four percent of surveyed PCPs and 48 percent of surveyed pain specialists who do not expect to prescribe tanezumab cite the high expected cost of the drug for the patient as a reason that they would be unwilling to prescribe the drug. As a biologic therapy, tanezumab is expected to be priced at a considerable premium over traditional oral analgesics.

"Although the responses of surveyed physicians suggest that efficacy and safety/tolerability are the most important factors influencing treatment decisions for chronic pain, these physicians anticipate that patient out-of-pocket costs and reimbursement constraints will directly influence their prescribing of emerging chronic pain therapies," said Decision Resources Principal Business Insights Analyst Natalie Taylor, Ph.D. "Even if an emerging therapy demonstrates significantly greater efficacy than the current standard of care for reducing pain, we find that both surveyed PCPs and pain specialists consistently assign lower anticipated patient shares to emerging therapies if the agents were to be covered by MCOs as non-preferred brands. However, emerging therapies that lower the overall long-term costs of treating chronic pain conditions may potentially secure more favorable reimbursement status from MCOs."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Collegium Announces Results of Chronic Pain Patient Survey - Confirms Significant Unmet Medical Need for a Differentiated, Abuse-Deterrent, Extended-Release Opioid
2. KemPharm Supports Recent FDA Recommendations for Hydrocodone-Containing Compounds and Abuse-Deterrent Opioids
3. Abuse-Deterrent Medication Developer, Pisgah Laboratories, Achieves Top 5 Technologies Ranking
4. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
5. XCHC Releases Worldwide Growth Guidance For Its Cannabinoid Treatment Centers and Formulations Targeting Critical Human Ailments, Company Acts on Own Guidance
6. Biodel Awarded NIH Grant to Develop Concentrated Ultra-Rapid-Acting Insulin Formulations for Use in Artificial Pancreas
7. Par Formulations (Formerly Edict Pharmaceuticals) Receives First ANDA Approval
8. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
9. Biodel Obtains Exclusive License to Aegis Therapeutics Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations
10. Valeant Pharmaceuticals To Announce 2013 Second Quarter Results On August 7, 2013
11. GW Pharmaceuticals to Report Q3 2013 Results and Host Conference Call on 5 August, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
(Date:6/23/2016)... , June 23, 2016 ... Oticon , industry leaders in advanced ... launch of Oticon Opn ™, the world,s first ... of possibilities for IoT devices.      (Photo: ... Oticon introduces a number of ,world firsts,: ...
(Date:6/23/2016)... , June 23, 2016  Experian ... integrating and transforming the patient payment and ... several innovative new products and services that ... its revenue cycle offerings. These award-winning solutions ... efficient workflows, remain compliant in an ever-changing ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their ... Eyeglasses . , Millions of individuals in the United States and Canada wear eyeglasses. ... way to both correct vision and make a fashion statement. Even celebrities use glasses ...
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
Breaking Medicine News(10 mins):